Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension

Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Keiichi Fukuda, Masaharu Kataoka

研究成果: Article査読

抄録

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36–49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response.

本文言語English
論文番号101592
ジャーナルRespiratory Medicine Case Reports
36
DOI
出版ステータスPublished - 2022 1月

ASJC Scopus subject areas

  • 呼吸器内科

フィンガープリント

「Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル